Search company, investor...

Progenitor Life Sciences

Founded Year



Unattributed | Alive

Total Raised


Last Raised

$110K | 9 yrs ago

About Progenitor Life Sciences

Progenitor Life Sciences is a Utah-based biotechnology company focused on the development and commercialization of research platforms for immune-oncology development applications, including chimeric antigen receptor (CAR) technologies.

Headquarters Location

675 Arapeen Drive Suite 302

Salt Lake City, Utah, 84108,

United States


Missing: Progenitor Life Sciences's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Progenitor Life Sciences's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Progenitor Life Sciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Progenitor Life Sciences is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest Progenitor Life Sciences News

Progenitor Life Sciences to Unveil Proprietary Next Generation “Off-the-Shelf” CAR-T Cell Development Workflow at the Biotech Showcase™ Annual Conference

Jan 3, 2018

Progenitor Life Sciences to Unveil Proprietary Next Generation “Off-the-Shelf” CAR-T Cell Development Workflow at the Biotech Showcase™ Annual Conference January 03, 2018 10:00 AM Eastern Standard Time SALT LAKE CITY--( BUSINESS WIRE )--Progenitor Life Sciences LLC today announced that it will present at Biotech Showcase™ 2018, January 8–10, during JPMorgan Healthcare Conference week. Gary R. Sams, CEO, will present Wednesday January 10 at 10:45 a.m. PST. Progenitor Life Sciences has developed a proprietary workflow to enable the Next Generation CAR-T development, including proprietary technologies for both autologous and “Off-the-Shelf” allogeneic approaches to therapy. The company’s technologies were developed by Progenitor in collaboration with the University of Utah. The company also announced that it will open discussions for a Series A investment round to fund further development of its platform and prosecution of IP. Sams stated, “We are excited to present at Biotech Showcase™. This event will be an extraordinary opportunity for Progenitor to highlight our unique CAR-T engineering platform, including new gene-switch technologies that allow control over CAR-T activity in vivo using medically safe small molecules, or by ‘programming’ cells in advance to respond automatically to specific environmental cues. The next generation of CAR-T cells will be safer and smarter, and Progenitor is leading the way with proprietary technologies that will be at the core of these new therapies. We look forward to engaging parties at Biotech Showcase™ and JPM who have interest in participating in our Series A round, as well as strategic collaborators who want to use our platform.” Biotech Showcase™, produced by Demy-Colton and EBD Group, is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences, the J.P. Morgan Annual Healthcare Conference. About Progenitor Life Sciences Progenitor Life Sciences provides unique and proprietary technologies to the rapidly growing immune oncology CAR-T development marketplace. The company is addressing key needs using proprietary genetic design approaches to enable next generation “off-the-shelf” allogeneic approaches, as well as, improved autologous approaches, to immune oncology CAR-T cell therapy development. The company’s products and technologies provide unique proprietary genetic design tools and cell constructs, which are used in the preclinical drug discovery and development process. Contacts

Progenitor Life Sciences Frequently Asked Questions (FAQ)

  • When was Progenitor Life Sciences founded?

    Progenitor Life Sciences was founded in 2012.

  • Where is Progenitor Life Sciences's headquarters?

    Progenitor Life Sciences's headquarters is located at 675 Arapeen Drive, Salt Lake City.

  • What is Progenitor Life Sciences's latest funding round?

    Progenitor Life Sciences's latest funding round is Unattributed.

  • How much did Progenitor Life Sciences raise?

    Progenitor Life Sciences raised a total of $110K.

  • Who are the investors of Progenitor Life Sciences?

    Investors of Progenitor Life Sciences include University of Utah.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.